所在位置:首页
 > ... > ABOUT CHINA MEDICAL CITY
 
ABOUT CHINA MEDICAL CITY
发布日期:2020-01-19 14:17 浏览次数: 字号:[ ] 信息来源:区政府党政办

China Medical City (Taizhou Medical High-tech Zone) is located in Taizhou, an important city in Yangtze River Delta. China Medical City covers 30 km2 according to its plan, consisting of functional zones of Scientific Research and Development, Manufacturing, Exhibition and Trade, Healthcare, Education and Teaching, and Comprehensive Supporting. As the first national level life science hi-tech park, CMC is jointly built by Ministry of Science and Technology, National Health and Family Planning Commission, China Food and Drug Administration, China Administration of Traditional Chinese Medicine and Jiangsu Provincial Government.

We are committed to building the largest life science industrial base with the most integrated industrial chain in China. CMC has cooperated with over 70 famous life science research and development institutes at home and abroad, and over 1000 companies with a large number of major industrial projects has been introduced, including AstraZeneca, Boehringer Ingelheim, Nestle, Sanofi-Pasteur, Takeda, Chugai, Taiwan Xantia, China Shijiazhuang Pharmaceutical Group, Neptunus Group, Watson, the antibody pharmaceutical manufacturing base of Mabtech, the vaccine projects of Zhongchong Group and Sinovet, Taiwan Jinying Biotech and SOL-Millennium, etc. More than 2100 word-class life science innovation achievements have been successfully declared. Over 4000 high level talents from home and abroad have settled down to establish the business. There is one winner of The Top National Science and Technology Award, 8 academicians of Chinese Academy of Sciences, Chinese Academy of Engineering and academicians from developed countries, 55 National innovative leading talents, 7 National Outstanding Youth Fund winners, and 5 Yangtze River Scholars approved by the Ministry of Education. 20 km2 have been developed. CMC has been classified as the National Hi-tech Zone, National Biology Industry Hi-tech Base, Medical Industrial Base of the National Torch Plan, National Science and Technology Export Innovation Base, National Life Science Export Base, National Demonstration Base for New industry, National Base for International Scientific and Technological Cooperation, National Industrial Base for Birth Control Apparatus, National Industrial Cluster of New Vaccines and Special Diagnostic Reagents, National Demonstration Zone for Health Tourism, National Pilot Projects of innovative industrial Clusters, Jiangsu Modern Service Industry Cluster, Jiangsu Medical Public Service Platform, Jiangsu Major Logistic Base and Jiangsu Major Industry Cluster, Jiangsu CFDA CMC Branch, Jiangsu Food and Drug Inspection Institute CMC Branch, Jiangsu Medical Device Testing Center CMC Branch have been established successively to better support the industry and offer services to the companies more efficiently.

China Medical City, a place nearest to your dream!

China Medical City, a new city for life science industry in China, your first choice for investment!

 

 

ABOUT TAIZHOU

Taizhou, a famous historical and cultural city in China, is located on the northern bank of the Yangtze River and in the north of the Yangtze River Delta. It is one of the central cities in the Shanghai metropolitan area.

Taizhou, with a history of over 2100 years, was named Haiyang in the Qin Dynasty (221 BC) and Hailing in the Han Dynasty (202 BC). It viewed the establishment of prefectural administration in the Southern Tang Dynasty (937 AD) and its culture thrived in the Northern Song Dynasty (960 AD). For thousands of years, with its favorable climate for the crops and peaceful environment for the people, Taizhou has been praised as the city of fortune and happiness, and a land of peace and harmony. Taizhou was the top city in the south of Huai River for its prosperous Confucianism. It’s the birthplace of many celebrities such as Wang Gen, Liu Xizai, Shi Nai'an, Zheng Banqiao and Mei Lanfang in Taizhou's cultural art history. Taizhou also boasts numerous scenic spots and historical sites, such as Guangxiao Monastery, Chongru Temple, Chenghuang Temple, Anding Academy, Wanghai Pagoda, Mei Lanfang Memorial Museum and the Memorial Museum of the PLA Navy Birthplace. They embody historical inheritance and cultural variety. Taizhou is also well-known for its eco-environment and picturesque scenery, including Qinhu Wetland Park, Canola Flowers on Thousands of islands, Water Forest, Tiande Lake Park and the Ancient Ginkgo Forest. Marco Polo said that the city isn't very big, yet full of worldly happiness when he traveled to Taizhou over 700 years ago. All the cities and counties affiliated to Taizhou have been built and selected as the National Ecological Demonstration Zone and National Top 100 Counties. Taizhou is China’s National Civilized City, National Model City for Environmental Protection, National Garden City, China Top Tourist City and National Advanced City for Science and Technology Progress.

 

 

LOCATION AND TRANSPORTATION

Taizhou is the portal to the middle of Jiangsu Province and an important city for transportation in the Yangtze River Delta. It has been called a key ferry crossing both in the waterway and ground transportation. The superior location and the integrated setup of highway, railway, waterway and airlines make Taizhou an important transportation hub in the north of Yangtze River Delta.

 

By Air

The Yangzhou Taizhou Airport is only 40 kms away from CMC, with 30 domestic flights connecting Beijing, Guangzhou, Shenzhen, Xi'an, and other major cities in China, and 5 international flights to Hong Kong, Taiwan, Japan, Korea and Thailand, etc. CMC can be connected to 5 adjacent international airports in Nanjing, Wuxi, Changzhou and Shanghai within 1-3 hours.

 

By Railway

There are 2 express trains to Beijing and multiple bullet trains to Nanjing in the Ningqi Double- Line Railway. The 6 passenger railways departing from Taizhou including Xinchang and Ningqi Railways can directly connect 63 important cities in China. Yantaixiyi Interurban Railway from south to north and the North Yangtze River-side High Speed Railway from east to west which can reach Shanghai, Nanjing, Wuhan and Chengdu are under construction. Upon completion, it will take about 40 minutes from Taizhou to Shanghai and to Nanjing.

 

By Highway

Xinchang, Ningqi, Jinghu, Ningtong, Yanjing and Qiyang Highways intersect throughout the whole territory.

 

By Waterway

Taizhou Port, a national first class open port, is 17 km away from China Medical City. Located on the northern bank of the Yangtze River, Taizhou Port is an important port for the transfer of materials from the upper and middle reaches of Yangtze River, Taizhou Port is also a hub connecting the transportation from the river, sea, railways and highways, supporting import and export services. As one of the supporting ports in the Shanghai Port Complex, Taizhou Port is the branch line and feeder port for the international transportation of containers. The port can offer comprehensive services including loading and unloading, storage and logistics.

 

 


CMC ADVANTAGE

Since the founding of China Medical City, we have actively built an industrial development environment by releasing preferential policies on taxation, manufacturing plant, product varieties, as well as science and technology support. At the same time, the incentives will be updated in due course by communicating with the industrial management organizations, according to the global trend of the life science industry and the national industrial policies. CMC focuses on creating a soft environment with prominent advantages to facilitate the sound the fast development of the industry.

 

One-stop Company Service

Taizhou Medical High-tech Zone Government Affairs Service Center was founded on August 9, 2014. There are 18 departments and units, 303 approval and management services and 67 windows with 80 staff at present. The center operates well, with an average daily reception of nearly 300 people. Since its operation, the center has always adhered to the principle of “convenient, efficient, incorruptible and standardized services". We constantly innovate the service model for government affairs, carry out multiple rounds of activities to increase speed and efficiency and make the government services more standardized

 

A Fast Product Registration System

Jiangsu China Food and Drug Administration, CMC Branch is the first branch affiliated to a provincial level CFDA in China. The branch executes the same power with the Jiangsu CFDA within the scope of China Medical City. The Branch has made full use of the mechanism of "co-building CMC by national ministries and Jiangsu provincial government" by gathering all the resources in CFDA, Jiangsu CFDA, Medical Device Testing Center and Institute for Food and Drug Control. The training of personnel has also been strengthened. We have helped with the registration and operation of projects with all our support by organizing experts for pre-approval, model examination, onsite teaching and observation, so as to upgrade the industrial level and facilitate the integration of industry factors. Jiangsu Institute for Food and Drug Control, Port of Entry and Medical Device Testing Center CMC Branches have also been established successively. It has greatly accelerated the product approval process and helped the companies in CMC to seize the market at an early date

 

Public Service Platforms

CMC has always viewed the construction of more functional and efficient public service platforms as the key to increase the core competitiveness ever since CMC was built at the beginning. The public service platforms can cover the whole process of life science industry. They are built in an international standard, led by the government, constructed by the companies, operated by the market and managed by professionals. Up to now, a number of public service platforms have been built and put into operation, including Macromolecular and Small Molecular Drug Research Center, Vaccine Engineering Center, etc.

 

21 Public Service Platforms

New Drug Incubator Service Platform

Covering an area of about 40, 000 m2, the New Drug Incubator Service Platform is planned and constructed according to the concept of "Entire R&D process and full services". It mainly speeds up the incubation of new drugs at home and abroad by providing large-scale equipment sharing, coaching for start-up business, technical training and other services to meet the needs of research and development for SMEs, so as to accelerate the industrialization of new drug incubation. The platform can accommodate 100 R&D projects, 80 talent teams and 150 new drugs at the same time

 

Large Scale Equipment Sharing Service Platform

The platform is mainly targeted at large scale scientific instrument and equipment, analysis and testing services, testing methods and standard research. Through the integration, optimal allocation, rational distribution and open sharing of related resources, the platform improves the usage effectiveness of equipment and resources, provides support for scientific and technological innovation and decision-making basis for the government. Therefore, the public resources can be managed unitively and shared efficiently. The large scale equipment has been standardized, modernized and scientifically managed. Resources have been rationally allocated to facilitate the management and use of the equipment. The utilization of equipment has been enhanced, the resources are shared, and the costs and risks of new drug innovation and manufacturing are reduced.

 

Analysis and testing Platform

The platform provides chemical and biomedical research companies with services including equipment configuration, analytical method development, standards research, personnel training, and the formulation of standard operating document. The platform, in accordance with national and international regulations and standards, has been approved by the National Accreditation Board with the CNAS laboratory accreditation certificate. Two major laboratories for chemical and biotechnology drugs have been constructed, covering 3000 m2. The platform is equipped with high-resolution liquid chromatography, atomic absorption spectrometer, fourier transform infrared spectroscopy, fluorescence quantitative PCR instrument, nucleic acid extraction instrument, fermenter, bio-analyzer, freeze dryer and other equipment for the research and development of chemical and biological drugs.

 

New Formulation Research and Development Platform

A new research and development platform for pharmaceutical preparations has been set up, including solid dosages and lyophilized preparation workshops. A quality control system has been established in accordance with the GMP requirement. With a complete set of equipment for drug formulations, the platform can offer advanced pharmaceutical technical services, including the prescription design of sustained release and targeting formulation, technical incubation, performance assessment of sustained release and targeting formulation, preparation process improvement and pharmaceutical adjuvant development.

 

Medical Information Retrieval Platform

The Medical Information Retrieval Platform is established in cooperation with Jiangsu Science and Technology Information Institute. Enterprises in the park can carry out free literature query service to wangfang, VIP, CNKI, SCI, CA and elsvier databases. The content of the platform also includes the network information retrieval tools -- search engine, important domestic and foreign medical websites, special information resource retrieval, communication, identification and evaluation of medical information, medical health technology, information sharing and intellectual property rights.

 

Public Service Platform for Small Molecular Drug Development

Covering an area of 6000 m2, the platform has advanced instruments and equipment and a complete research and development team. With world-class quality control and management system, a platform for the design, screening, evaluation, research, development and engineering of original small molecular drugs has been established. The platform focuses on the research and key technologies for the commercialization of original small molecular drugs for major diseases including oncology, immunological and metabolic diseases. A batch of original small molecular drugs have been developed and manufactured. For example, AT 101, an original drug of Jiangsu Ascentage Pharma, one of the onsite companies, has entered the stage of phase II clinical trial.

 

Public Service Platform for Macromolecular Drug Development

With the United States as the core technology support and China as the industrial development base, the platform is built in accordance with the strategy of “Starting in China and going to the world”. The platform can provide CRO and CMO services for various kinds of biotechnology drugs for the large number of small and medium-sized pharmaceutical research companies. It can effectively reduce the cost for early stage research and overcome technical obstacles for drug research startup companies, so as to promote the registration and industrialization of high-tech biomedical projects.

 

Platform for Molecular Diagnosis Technologies

With a floor space of 3296 m2, the platform consists of 3 parts: a research and development platform for molecular diagnostic products, a trial production line and a product evaluation center. The center mainly serves the domestic and foreign companies for the research, development and manufacturing of innovative in vitro diagnostic (IVD) reagents. The SMEs can enjoy lower prices but high- level research and manufacturing services. The platform can also offer incubation services for IVD research companies.

 

Gene Sequencing Technology Service Platform

The Gene Sequencing Technology Service Platform is operated and managed by the team led by Professor Xie Xiaoliang, a member of the American Academy of Sciences. Using the single-cell gene sequencing technology, the platform focuses on building the advanced high-throughput gene sequencing technology service platform, which avoided the inevitable magnification bias in the PCR response to the extremely small initial template by conventional methods, and addressed the important impact that a few or even very few cells in the cell community often have on diagnosis, treatment and prognosis assessment. Relying on high-throughput sequencing platforms and high-performance computing platforms, the existing services are mainly targeted to the scientific research market. The platform can provide bioinformatics services such as genome sequencing of plants, humans, animals and micro-organisms, RNA sequencing and exon sequencing for many universities and scientific institutes.

 

Vaccine Engineering Center

Invested and built by China Medical City, the Vaccine Engineering Center is an integrated technology incubation and product transformation center affiliated to Taizhou Medical Hi-tech Zone Administrative Committee. Covering a total floor area of 46,000 m2, the center mainly includes the functions of vaccine research and development, process development for pilot trials, inspection and testing, clinical evaluation, storage of bacterial and viral strains.

The center was approved as the Jiangsu (Taizhou) Vaccine Engineering Technology Research Center by Jiangsu Provincial Science and Technology Department in September 2010. The center was also approved as Jiangsu Provincial Center for the Application and Engineering of New Vaccines by Jiangsu Provincial Development and Reform Commission in September, 2012.

 

High-end Medical Device Research and Development Platform

The center is composed of Jiangsu Provincial Medical Device Inspection Institute, CMC branch and dozens of high-tech medical device companies with strong innovation ability and huge potential. It is a comprehensive service platform integrating research, development, manufacturing, testing, registration and sales of medical devices and biological diagnostic reagents. A number of high-tech products have been commercialized in China Medical City, including high magnetic resonance instrument, avian flu detection chip, artificial skin, hand-foot-and-mouth disease detection kit, etc.

 

Research and Development Platform of Modernized Traditional Chinese Medicine

Based on the scientific research and talent resources of Nanjing University of Chinese Medicine, the Research and Development Platform of Modernized Traditional Chinese Medicine combines the advantages of traditional Chinese medicines all over China, offering services of standard cultivation of herbs, prescription screening, clinical trials and new technology research.

 

Contract Manufacturing Organization Service Platform

Contract Manufacturing Organization (CMO) Service Platform is mainly set up by Jiangsu Yaohai Biopharmaceutical Co, Ltd to provide the pilot test for macromolecular and small molecular drugs and the pre-production of drugs for clinical trial. The platform can also provide CMO services for monoclonal antibodies, polysaccharides, polypeptide, nucleic acid and proteins. It can meet the demand of more than 20 dosage forms and hundreds of drugs.

 

Research and Development Platform of Cell and Protein Therapy

The Research and Development Platform of Cell and Protein Therapy is mainly engaged in the research and development of fusion protein, the research and application of somatic therapy, organ transplantation and translational medicine. At present, a comprehensive technology platform has been built, which includes Molecular Biology Platform, High-expression Cell Line Screening Platform, Protein Expression Purification and Pilot Trial Platform and Human-derived Antibody Development Platform. The platform has successfully developed more than 600 fusion protein products with new immunomodulatory functions. The first batch of products was officially exported through customs in July 2010, which is the first for fusion protein product approved for export in Jiangsu Province.

 

Intellectual Property Protection Service Platform

The intellectual Property Protection Service Platform is a public platform set up to provide protection for patents, trademarks and business confidentiality for the onsite companies in CMC, because the life science industry is largely dependent on patents. Besides, Jiangsu (Taizhou) Medical Technology Property Rights Trading Center and Jiangsu Complaints Report Center for Intellectual Property Rights Protection, CMC Branches have also been established. Tazhou Diyi has been introduced as an agency to process patent application in life science industry.

 

Third Party Drug Logistics Service Platform

A modern pharmaceutical logistic warehouse and business trading center in line with GSP standard have been established. The platform has the qualification of the third party drug logistics with a drug logistics system and a cold chain distribution system covering the whole country. A number of well-known domestic and international companies including Takeda, CSPC and NT Pharma have settled down on the platform successfully.

 

New Drug Safety Evaluation Center

The New Drug Safety Evaluation Center was built by CMC and Chengdu Safety Evaluation Center by making use of the hardware resources in CMC. The center can provide the onsite companies with specialized technical services such as drug screening under non-GLP conditions and animal drug safety evaluation, by researching the experimental animal standards and testing techniques, animal safety evaluation standards and methods of various drugs and vaccines.

 

Dalian Institute of Chemical Physics, Chinese Academy of Sciences Jiangsu (Taizhou) Institute of Biomedical Innovation

Located in Building D in Research and Development Area of CMC, the institute mainly relies on the talent and technical advantages of the Chinese Academy of Sciences and Dalian Institute of Chemical Physics, combing the advantages of Taizhou life science industry to meet the industry demand. The innovation is jointly facilitated by the government, industry, academia, research and resources. We shall build the institute as a source of common technologies, a cluster of high level research institutions, an incubation center for hi-tech companies, a strategic think tank of industrial technology and a hub of technical talents We shall build a leading domestic and international biotechnology research and development service platform, industrial incubation platform and the technology transfer center. Among them, the institute shall focus on the theme of traditional Chinese medicine and health, aiming at developing precision traditional Chinese medicine, health research institution and industrial incubator to meet the local industrial demand.

 

Immunotherapy Platform

The Immunotherapy Platform includes the Immune Cell Therapy Platform, the Immune Diagnosis Technology Platform and the Immune Detection Service Platform. The Immune Cell Therapy Platform will be operated in the way of managing a project entity, so as to promote the specific implementation of the project, build the technical team and enhance the platform technology level. The Immune Diagnosis Technology Platform and the Immune Detection Service Platform are mainly building the talent team and operating the platform, using the method of technology research and transfer. The platform can provide the related services of immune diagnosis, immune detection and immune function evaluation to meet the demand of the companies.

 

Large Animal Experiment Center

Large Animal Experiment center, As a pre-clinical accelerator, located in China Medical City, is a professional large animal preclinical research center specializing in preclinical evaluation of medical devices and integrated service of products research. As a third-party service platform, we have the normalized breeding base, the most professional technical team, top-quality service system and high standardized quality management. The advanced apparatus contained MRI, C-arm X-ray and anesthesia machine. Based on this, we have completed some preclinical tests of the medical devices, such as artificial vessel, cardiac valve, hemostatic materials, and orthopedic devices.

 

China Medical City Clinical Research Base

China Medical City clinical research base is located on the 12th to 15th floor of the inpatient department of Taizhou integrated hospital of Chinese and western medicine. The team consists of national GCP inspectors, senior clinical research experts, clinical sample analysis experts, data management and statisticians and other professional experts, and is committed to integrating the advantageous resources of China Medical City, to become the largest and best clinical trial base in China. The base focuses on the clinical research of drugs and medical devices, and can provide pharmaceutical companies with clinical trials of new drugs, quality consistency evaluation of generic drugs, clinical trials of medical devices, central laboratory, data management and statistical analysis, and clinical technology consultation.

 

Special Financial Services

At present, CMC has set up a total of 30 funds with an amount of nearly 300 billion yuan (10 billion yuan innovation fund for Category 1 new drug). A number of entities have been established including a small load guarantee company, a “credit system” platform, a “financial supermarket" and a Listing Office which creates a fast track of listing on the "New Three Board". A total of 28 companies and agencies have signed listing cooperation agreements and we actively support the companies to seek financing by listing on the stock market. CMC is creating the CMC National New Drug R&D Investment Fund. A modern capital mechanism of relying on government subsidies at the start-up period, science and technology credit at growth stage, direct equity financing in mature stage and listing support at expansion period, has gradually taken shape.

 

China Medical City Financial Supermarket is open to all the companies in CMC. We can help to design proper financing proposals and offer tailor-made financial consulting services to companies in CMC, with all the financial industrial resources in CMC, based on the related requirement of the companies and the advantages of different companies. For the companies that have financing need and equity investors with investment demand, the Financial Supermarket can help them find suitable partners for them and build a bridge to reduce communication costs between the two sides. In addition to building three major platforms including equity investment, debt financing and financial agency platforms, we shall also organize training, financial promotion conferences, project road shows, special equity training, industry resources development activities, venture competition and a series of branding activities. Therefore, we can better promote the communication and interaction between companies and investors, thus creating a mechanism for open cooperation and mutual benefit for talents, technology and capital. CMC is also actively promoting the overall listing work to expand financing channels.

 

Innovative Leading Talent Team

We consider innovation as the theme and development the banner of CMC. After years of development, CMC has formed its own unique advantages, attracting the attention of the world pharmaceutical industry. CMC has become an attractive place for innovation and entrepreneurship in the life science industry. Since the start of construction, CMC has vigorously implement the strategy of boosting CMC by talents, introduced high-level talents and entrepreneur teams and pioneered the industry for leaping development. A new innovation-driven development mode has taken shape initially. At present, CMC has gathered more than 4000 domestic and international high-level talents, 55 National innovative leading talents, and 115 people are selected to the Jiangsu Provincial Innovative and Entrepreneurial Talents.

 

The Only Medical Park Co-built by National Ministries and Provincial Government

On February 25, 2010, a cooperation agreement was signed by the Ministry of Science and Technology, National Health and Family Planning Commission, China Food and Drug Administration, State Administration of Traditional Chinese Medicine and Jiangsu Provincial government to jointly build China Medical City. This has created a good environment to accelerate the construction of CMC at a higher level.

 

Division of Work between ministries and provincial government

Ministry of Science and Technology

To assist in the planning and development of China Medical City, to guide and support related research and development, industrialization and the introduction of talents and projects.

National Health and Family Planning Commission

Responsible for guiding and supporting the research and development of medicines

China Food and Drug Administration

We give guidance and support to the development, production and circulation of medicines, medical instruments and health food.

Provincial Government

Responsible for the planning and construction of China Medical City, the formation and implementation of relevant policies and to overcome difficulties and solve problems

State Administration of Traditional Chinese Medicine

It is responsible for the guidance and support of the development of traditional Chinese medicine.

 


 

MAJOR INDUSTRIAL PROJECTS

China Medical City has always put industrialization the top priority and highlighted the dominant position of projects ever since the construction began. We have gathered the medical resources from the world to constantly improve the whole medical and health industry chain. A number of major industrial projects have settled down successively with more and more clustering effect, including AstraZeneca, Boehringer Ingelheim, Nestle, Sanofi Pasteur, Takeda, Chugai, Taiwan Xantia, CSPC, Neptunus, Watson, etc.

 

Introduction to Representative Companies

1. Chemical Preparations

AstraZeneca Global Manufacturing Base

AstraZeneca’s production base in CMC is the company’s largest single investment in a manufacturing facility globally, covering 138 mu (92,000 m2). With an investment of 230 million USD, the first phase of the project is mainly for the research, development, production and sales of the world’s innovative medicines including cephalosporin, beta-lactam antibiotics, oral solid dosages and injections. It is targeted to build a base for pharmaceutical research, industrialization and sales in Asia.

2. Foods for Special Medical Purpose and Healthcare Products

Nestle FSMP Project

The project was invested and built in CMC by Nestle Health Science, the world-renowned company, mainly focusing on the research, production and sales of sterile oral nutritional products. The company plans to invest in a production base that meets GMP standards in about 5 years to meet the demand of sterile oral nutritional products in China. The project plans to invest 90 million USD, the first phase in the standard manufacturing plant to establish an annual production base with a capacity of 2000 tons, the second phase to establish a large-scale industrial base of 20,000 tons in the industrial zone of CMC.

3. Biological Products (Major Vaccines and Antibodies)

Boehringer Ingelheim Vaccine and Medical Product Base

Boehringer Ingelheim, the world’s largest biomedical CMO company and the largest pharmaceutical firm in Germany, has invested 90 million USD in building a research, development and manufacturing base of animal vaccines. With a registered capital of building a base for the research, development, production and sales of vaccines and medical products in Asia.

Convac Biological Vaccine Industrialization Base

The biological vaccine industrialization base is established by Jiangsu Convac Biotechnology Co., Ltd, with a total investment of 250 million yuan. The main products can fill the market gap with independent intellectual property rights, including inactivated poliovirus vaccine and hepatitis A vaccine. Convac's project has demonstrated and guided the construction of vaccine industrial base in China, and will attract the resources of vaccine industry at home and abroad.

Taizhou Mabtech Pharmaceutical Co., Ltd. Profile

Taizhou Mabtech Pharmaceutical Co., Ltd. joined the China Medical City (CMC) in 2015 supported by Mabtech holding Ltd (HK) and dedicated to the industrialization of a series of “blockbuster” innovative antibody drugs.

The First-period construction of the company is about 14600 square meters and put into production in July 2016, including the scale of 3×1500L Eukaryotic cell bioreactor and purification production line, 2 production lines of Aseptic preparation and fully functional QC laboratory.

Annual capacities of the First-period construction are 80 kilograms of antibody protein, 4 million branches of XiLin and 1 million preconditioning needles.

Currently, the Second period Mabtech Project has been started. It will construct three sets of 3×1500L Eukaryotic raw liquid production lines and expected to be completed and put into production at the end of 2019.

4. Traditional Chinese Medicine Formulation

Jiangsu Suzhong Pharmaceutical Group

Jiangsu Suzhong Pharmaceutical Group has a history of 40 years. As a large group of research, development, production and sales of pharmaceuticals, it is one of the National Top 100 Pharmaceutical Enterprises and a Model Company of Science and Technology Innovation in Chinese Medical Industry. It has built a Nation  Post-doctoral Workstationa Jiangsu Provincial Enterprise  Academician Workstation, Jiangsu Provincial Engineering Technology   Research  Center and Maidu Drug Institute in China Medical City. The company owns 6 national protected medicine varieties and 4 national key new products.

Jiangsu Suzhong Biotechnology Co, Ltd was established in CMC in July 2012, with an investment of 130 million yuan. Two modernized workshops for injection and extraction have been built. The company passed the onsite verification by the GMP expert group, becoming the first company in CMC to obtain the new GMP certification for injection.

5. High-end Medical Devices and High-value Consumables

Jiangsu Bioperfectus Technologies

Jiangsu Bioperfectus Technologies is mainly engaged in the research, development, production and sales of corresponding in vitro diagnostic reagents in infectious diseases, women’s Health, tumor detection and food safety, which was established in April 2010. It is a national high-tech enterprise. With nearly 400 self-developed products, Jiangsu Bioperfectus Technologies's clients are covering over 400 centers for disease control and 2,000 clinical institutions all over the whole provinces and regions in China.



【返回顶部】 【打印本页】 【关闭窗口】
Copyright© 2013 泰州医药高新技术产业开发区管理委员会 版权所有
联系方式:0523-89690209 网站标识码:3212900017
苏ICP05003226号-1
浏览请用IE7以上版本浏览器.建议分辨率1024x768及以上 ▏ 网站地图

苏公网安备 32120502010080号

Produced By 大汉网络 大汉版通发布系统